How much funding has Ashvattha Therapeutics raised?

Ashvattha Therapeutics has raised $188.0M in total funding, most recently a Extension Round.

Who are Ashvattha Therapeutics's investors?

Ashvattha Therapeutics's investors include Natural Capital, Tribe Capital, Kennet Partners, Insight Partners, Savant Growth, Khosla Ventures.

When was Ashvattha Therapeutics founded?

Ashvattha Therapeutics was founded in 2016.

Where is Ashvattha Therapeutics headquartered?

Ashvattha Therapeutics is headquartered in San Francisco, California, United States.

What industry is Ashvattha Therapeutics in?

Ashvattha Therapeutics operates in Biotech, Healthcare.

How many employees does Ashvattha Therapeutics have?

Ashvattha Therapeutics has 11-50 employees.

Ashvattha Therapeutics

formerly AVTTX

Developing a New Class of Intracellular Targeted Therapeutics

San Francisco, United States · Founded 2016 · $188.0M raised

Biotech

Healthcare

Headquarters: San Francisco, California
Employees: 11–50
Founded: 2016
Business Model: B2B

Website: avttx.com
Total Funding: $188.0M
Last Round: $50.0M Extension RoundJan 2025
Rounds: 3

About

Ashvattha Therapeutics is a clinical-stage biopharmaceutical company founded by Johns Hopkins scientists that develops hydroxyl dendrimer-based nanomedicines targeting activated microglia and macrophages in diseased tissue. Its lead program, migaldendranib (MGB), is in Phase 1/2 clinical trials for retinal and inflammatory conditions, with the technology enabling precise intracellular drug delivery without affecting healthy cells.

Summary

Ashvattha Therapeutics is a Biotech company based in San Francisco, United States, founded in 2016. It has raised $188.0M in total across 3 rounds, most recently a $50.0M Extension Round round in Jan 2025. Investors include Natural Capital, Tribe Capital and Kennet Partners.

LinkedIn X (Twitter)